NP and PA

Vector-borne infectious diseases are spreading and skin cancer is rising because of climate change.

The AAD has provided various at-home treatments for keratosis pilaris that physicians can recommend to their patients.

From oat oil to acupuncture to prebiotics, there are many topical, oral, and manual options.

Patients with anxiety/depression and psoriatic arthritis (PsA) are much less likely to achieve long-term remission. Mental health comorbidities need to be a more important part of PsA treatment.

Explore what dermatologic drugs the FDA will decide to approve during July 2021.

New TrichoTest aims to help clinicians diagnose and treat alopecia.

A higher prevalence of vitamin D deficiency in people of color may be contributing to a higher burden of COVID-19 in minority populations. Dermatologists are encouraged to address vitamin D status in patients and recommend supplementation, which might have other health benefits.

John Browning, MD, FAAD, FAAP, MBA, discusses the impact of the recent FDA approval of secukinumab (Cosentyx, Novartis) for the treatment of moderate to severe plaque psoriasis in children and adolescents.

Sunscreen is a necessary preventive tool. However, there are concerns about UV agent absorption, environmental impact, and possible correlations with frontal fibrosing alopecia (FFA). Here is a look at whether those worries are justified by research.

Recent therapeutic advances in topical and systemic therapy offer new options for cases that have not responded to established treatment approaches.

Diagnosis, risk assessment and treatment of congenital melanocytic nevi (CMN), as well as melanoma, require specific strategies for pediatric patients.

One expert says the action of demodex folliculorum and the composition of the symbiotic microbiota in the skin of patients with rosacea may provide valuable insights into the pathogenesis and pathophysiology of this widespread skin disease.

A recent study finds that payer sway in a region hurts not only patient care, but also physician pay.

Next-generation therapies explore solutions other than laser treatments, and are less invasive, safer and require less downtime.

Half of patients are satisfied with their atopic dermatitis treatment and more than half of patients worry about topical steroid side effects, addiction and withdrawal, according to a recent study.

The National Psoriasis Foundation’s (NPF) COVID-19 Task Force has recently published 22 guidance statements related to managing psoriatic disease during the pandemic in the Journal of American Academy of Dermatology (JAAD).

In recently presented data at the 29th annual European Academy of Dermatology and Venereology (EADV) virtual congress, baricitinib demonstrated significant long-term safety and efficacy in treating moderate-to-severe atopic dermatitis.

Only half of patients are satisfied with their atopic dermatitis treatment; yet, only about one-third discuss their quality-of-life concerns with their healthcare provider, a recent survey reveals.

Steven R. Feldman, M.D., Ph.D., describes several tactics based on concepts from behavioral economics that can be implemented in counseling conversations with patients.

ICYMI, this week’s edition features a video series on social media use in dermatology, the launch of our new podcast, as well as articles about FDA approvals for acne and cSCC, progress in epidermolysis bullosa, new rosacea management treatment, plus more.

Efforts are underway to identify new therapeutic methods that can offer improved outcomes for patients with hidradenitis suppurativa.

In light of the ongoing pandemic, Vivian Shi, M.D., discusses potential risks dermatologists will want to keep in mind when evaluating patients currently taking immunomodulator or immunosuppressant drugs.

Dr. Suneel Chilukuri of Refresh Dermatology located in Houston, Tx., sits down with Dermatology Times to discuss the aesthetic needs of millennial patients and what they've been requesting, such as treatment for 'tech neck' and much more.

A recent clinical review proves trifarotene 0.005% cream is an effective and safe treatment for acne vulgaris on the face and neck in patients 9 years and older. Currently, the drug is one of four topical retinoid acne treatments available on the market.